PHARMACOKINETICS AND EXPOSURE-RESPONSE FOR REGN1979, A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA.

被引：0
|
作者：
Yang, F. [1 ]
Zhu, M. [1 ]
Toroghi, M. [1 ]
Putluri, D. [1 ]
Yan, H. [1 ]
Davis, J. [1 ]
DiCioccio, A. [1 ]
机构：
[1] Regeneron Pharmaceut, New York, NY USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
OV-002
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [21] A pilot study of anti-CD20 MoAB rituximab in aids-associated non-Hodgkin's lymphoma.
    Barrett, JC
    Linn, CA
    Arani, RB
    Rosenberg, J
    Saleh, MN
    BLOOD, 1999, 94 (10) : 258B - 258B
  • [22] Anti-CD20 monoclonal antibodies as novel treatments for non-Hodgkin's lymphoma
    White, CA
    Larocca, A
    Grillo-López, AJ
    PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1999, 2 (03): : 95 - 101
  • [23] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Gui, Lin
    Han, Xiaohong
    He, Xiaohui
    Song, Yuanyuan
    Yao, Jiarui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Zhang, Shuxiang
    Zhang, Weijing
    Gai, Wenlin
    Xie, Liangzhi
    Shi, Yuankai
    CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (02) : 197 - 208
  • [24] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Lin Gui
    Xiaohong Han
    Xiaohui He
    Yuanyuan Song
    Jiarui Yao
    Jianliang Yang
    Peng Liu
    Yan Qin
    Shuxiang Zhang
    Weijing Zhang
    Wenlin Gai
    Liangzhi Xie
    Yuankai Shi
    Chinese Journal of Cancer Research, 2016, (02) : 197 - 208
  • [25] First-in-human study assessing safety and tolerability of REGN1979, a novel CD20xCD3 bispecific antibody, in patients with CD20+B-cell malignancies previously treated with anti-CD20 therapy.
    Brownstein, Carrie M.
    Adriaens, Lieve
    Bannerji, Rajat
    Chavez, Julio C.
    Levy, Ronald
    Ansell, Stephen Maxted
    Advani, Ranjana H.
    Patel, Snehal
    Kostic, Ana
    Trail, Pamela
    Lowy, Israel
    Kohrt, Holbrook Edwin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy
    Bannerji, Rajat
    Allan, John N.
    Arnason, Jon E.
    Brown, Jennifer R.
    Advani, Ranjana
    Ansell, Stephen M.
    O'Brien, Susan M.
    Duell, Johannes
    Martin, Peter
    Joyce, Robin M.
    Li, Jingjin
    Flink, Dina M.
    Zhu, Min
    Weinreich, David M.
    Yancopoulos, George D.
    Sirulnik, Andres
    Chaudhry, Aafia
    Ambati, Srikanth R.
    Topp, Max S.
    BLOOD, 2020, 136
  • [27] Preparing Nurses for CD20-CD3 Bispecific Antibody Treatment in Patients With Non-Hodgkin Lymphoma
    van der Linde, Sam
    Knights, Emily
    Robertson, Molly
    Krishnasamy, Meinir
    Minson, Adrian
    Dickinson, Michael
    CANCER NURSING, 2024,
  • [28] Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab
    Schmitz, K
    Brugger, W
    Weiss, B
    Kaiserling, E
    Kanz, L
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) : 571 - 572
  • [29] Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma
    Protheroe, A
    Edwards, JCW
    Simmons, A
    Maclennan, K
    Selby, P
    RHEUMATOLOGY, 1999, 38 (11) : 1150 - 1152
  • [30] Characterization of a Novel Humanized Anti-CD20 Antibody with Potent Anti-Tumor Activity against Non-Hodgkin's Lymphoma
    Zhang, Haifeng
    Song, Liping
    Ye, Hongtu
    Hu, Lide
    Liang, Wenlu
    Liu, Datao
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2013, 32 (03) : 645 - 654
12345